Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

4

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Vitamin D receptor

4

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

4

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1993

4

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Breast cancer

4

Colon cancer

4

Lung cancer

4

Plaque psoriasis

4

Unknown

4

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

4

Palliative

4

Primary

4

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Pharmaceutical Research Institute

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

4

PUBCHEM

4

CAS

3

CHEBI

2

ChEMBL

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

DERMATOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIPSORIATICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIPSORIATICS FOR TOPICAL USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other antipsoriatics for topical use

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

3

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 4 of 4 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

CALCIPOTRIENE

143NQ3779B

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1993

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Vitamin D receptor

Conditions:

Plaque psoriasis

5E-Calcipotriol is a geometric analog of vitamin D derivative calcipotriol. It was shown to enhance anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model and anticancer activity of imatinib in an in vivo lung cancer model. The ...

compound also demonstrated activity in a subcutaneous MCF-7 model of breast cancer in vivo. The detailed mechanism of action for 5E-calcipotriol is not known.

CALCIPOTRIOL, (5E)-

QRA3492A7Q

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1993

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Vitamin D receptor

Conditions:

Plaque psoriasis

5E-Calcipotriol is a geometric analog of vitamin D derivative calcipotriol. It was shown to enhance anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model and anticancer activity of imatinib in an in vivo lung cancer model. The ...

compound also demonstrated activity in a subcutaneous MCF-7 model of breast cancer in vivo. The detailed mechanism of action for 5E-calcipotriol is not known.

CALCIPOTRIOL, (7Z)-

075Y05GJ7L

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1993

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Vitamin D receptor

Conditions:

Plaque psoriasis

5E-Calcipotriol is a geometric analog of vitamin D derivative calcipotriol. It was shown to enhance anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model and anticancer activity of imatinib in an in vivo lung cancer model. The ...

compound also demonstrated activity in a subcutaneous MCF-7 model of breast cancer in vivo. The detailed mechanism of action for 5E-calcipotriol is not known.

CALCIPOTRIENE MONOHYDRATE

S7499TYY6G

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1993

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Vitamin D receptor

Conditions:

Plaque psoriasis

5E-Calcipotriol is a geometric analog of vitamin D derivative calcipotriol. It was shown to enhance anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model and anticancer activity of imatinib in an in vivo lung cancer model. The ...

compound also demonstrated activity in a subcutaneous MCF-7 model of breast cancer in vivo. The detailed mechanism of action for 5E-calcipotriol is not known.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1